This study evaluated the effects of milrinone, adrenaline and dobutamine with pressure-volume loops and isolated atrial tissue.
Milrinone is a phosphodiesterase III inhibitor, raising intracellular levels of cyclic adenosine monophosphate (cAMP). It is classed as an inodilator, possessing both inotropic and vasodilator properties. Milrinone caused positive inotropy in isolated canine tissue 1 , guinea pig papillary muscle 2 and left atrium 3 . In vivo, milrinone improved ejection phase indices of myocardial performance such as cardiac output and ejection fraction 4 may include improvement in right ventricular function associated with pulmonary vasodilation 5 and improvement in early ventricular relaxation 6 .
In clinical use milrinone has invoked much controversy. When used intravenously in acute cardiac failure, severe systemic hypotension is a frequent complication requiring cessation of the drug or vasopressor support 7 . There appears to be a predominance of vasodilator to inotropic effects, with resultant systemic hypotension. Of greater concern, morbidity and mortality associated with the use of milrinone. The oral formulation of milrinone was advocated as a replacement for digoxin in long-term treatment of heart failure, but was discontinued after bidity and mortality in the milrinone group 8 . Cuffe et al 9 randomised 951 patients with exacerbations of chronic heart failure to receive 48 hours of intravenous milrinone (0.5 μg/kg/min) or placebo. Although there was no difference in outcome (cumulative hoscantly higher incidence of sustained hypotension and atrial arrhythmias in those receiving milrinone.
Ejection phase measurements of systolic function and those derived from left ventricular pressure tracings may give misleading results when the drug has considerable vasodilator properties. Vasodilation facilitates ejection and causes earlier opening of the aortic valve, leading to increased ejection fraction but reduced maximal dP/dt. Pressure-volume loops have been used to measure the effects on contractility and diastolic function in anesthetised animals independent of loading conditions and additionally measure the effects of drugs on the systemic circulation 10, 11 . Isolated tissue preparations allow direct inotropic and chronotropic drug actions to be assessed at concentration-effect equilibrium and or hormonal changes in vivo.
The aims of this study were to characterise the myocardial and circulatory effects of milrinone and the conventional catecholamine inotropes adrenaline and dobutamine in vivo using pressure-volume loops in anesthetised rabbits and in vitro using guinea pig isolated atria.
METHODS
The Animal Ethics Committee of the University of Melbourne approved the investigation which conforms to the Guide for the Care and Use of Laboratory Animals, published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Anesthetised rabbits
Eleven male New Zealand white rabbits (2.1-2.3 kg) were anaesthetised with propofol (10 mg/kg bolus, then 50-100 mg/kg/h IV), intubated and mechanically ventilated. Core temperature was maintained at 39°C using a Harvard warming blanket (Edenbridge, Kent, U.K.). The heart was exposed via median sternotomy and a 3-French combined micromanometer pres-Millar Instruments, Texas, U.S.A.) was inserted into the left ventricle (LV) through an LV apical stab.
system incorporating a micromanometer that has a high frequency response to 10 KHz. A silicone sling was placed around the inferior vena cava (IVC), in catheters were inserted into the right internal jugular vein and advanced to the right atrium; and into the right carotid artery. The animals were killed at the end of the study with pentobarbitone 100 mg/kg (IV).
Agonist dose-response curves were obtained for adrenaline, followed by dobutamine, then milrinone (studied last because of its prolonged half-life). Drugs were administered (IV) by incremental infusion every 10 minutes in order to allow relatively stable plasma levels and for milrinone, to allow time for development of peak effect 12 . The infusion rates for adrenaline and dobutamine were 0.1, 0.2, 0.4, 0.8 μg/kg/min and 10, 20, 40, 80 μg/kg/min, respectively. The doses of milrinone were 20, 40, 80, 160 μg/kg each administered as an infusion over one minute.
Pressure-volume measurements
The electrical impedance, measured using three segments within the left ventricle, was recorded with a CFL-512 cardiac function laboratory and analysed off-line with proprietary software (CD Leycom, data were simultaneously acquired and displayed with impedance measurements as real-time pressurevolume loops. Five ml of blood was withdrawn for Volume calibration was performed by injection of 0.07 ml/kg of 10% saline into the right atrium 13, 14 with measurement of the parallel conductance (V c ). Data for load-independent measurements were obtained (3-5 sec).
Acquired primary data included carotid artery mean arterial pressure (MAP), right atrial pressure (RAP), heart rate (HR), continuous LV pressure and LV volume.
The following measurements were performed on Cardiac index (CI)=(stroke volume (SV)×heart rate (HR))/body weight (l/min/kg). Systemic vascular resistance index (SVRI)= ((MAP-RAP)/CI) 80 dyn×s/cm 5 /kg. Ejection fraction (EF)=(end-diastolic volume -end-systolic volume)/end-diastolic volume (%). Isovolumetric relaxation pressure half-time (Tau) =time from end-systole until pressure declines by half (method of Weiss). From pressure-volume loops: PRSW=preload recruitable stroke work (mmHg). PRWS is the linear regression of the pressure volume (PV) loop area and enddiastolic volume, measured during acute preload reduction.
EDPVR=end-diastolic pressure-volume relation (mmHg/ml). The sample size was based on previous studies aiming to identify a 20% difference between groups in our primary endpoint (PRSW) with power 0.8 and alpha 0.05. The minimum sample size was 10 rabbits and we included an additional rabbit in case there were technical problems with analysis.
Isolated atria
Eight tri-colour guinea pigs (240-390g) were anaesthetised in a mixture of 80% carbon dioxide and 20% oxygen and killed by exsanguination. The heart was then rapidly excised and placed in warmed, oxygenated Krebs' solution (PSS, composition (mM): NaCl 119, KCl 4.69, KH 2 PO 4 1.18, glucose 11, NaHCO 2 1.
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--ADRENALINE, DOBUTAMINE AND MILRINONE 25, CaCl 2 2.5, EDTA 0.026 and gassed with O 2 95%: CO 2 5% at 37°C and pH 7.4). The atria were removed and separated. Tissues were suspended across two platinum punctate electrodes embedded in a tissue holder in a 15 ml jacketed organ bath, containing PSS gassed with 95% oxygen and 5% carbon dioxide. An initial force of 0.5 g was applied to spontaneously beating right atria. Initial left atria resting force was 0.2 g and continuous 1 Hz punctate stimulation (1.5 threshold V, 5 ms duration) was applied to drive the atria. An optimal length-tension curve was determined by increasing the resting force in 0.1g increments to a maximum of 1.0g. The tissues were then reset to a resting force that gave 80% of maximal active force to this procedure. Data were acquired as a continuous trace using a multi-channel chart recorder (Neomedix Systems, Sydney, Australia). Adrenaline, dobutamine and milrinone were added as cumulative concentrations starting at a minimum concentration of 10 -9 M, up to a maximum of 10 -5 M. The concentration of drug used in the anesthetised rabbit preparation was within the 10 -6 to 10 -5 M range, assuming a plasma volume of 60 ml/kg in the animals. All tissues were allowed to equilibrate in drug-free Krebs' solution for 60 minutes prior to addition of the next drug. Drugs were added to the tissues sequentially but in random order to minimise bias due to a fall in baseline force. Force measurements were taken as the value during the plateau in the tissue response.
Statistical analyses
Continuous data were analysed using repeated measures ANOVA for within subject differences for P<0.05. Data are expressed as mean ±SEM. For data presented in graphs, the error bars indicate the average within-subject SEM for each drug SPSS for Windows v12 (SPSS Inc., Chicago, U.S.A.).
RESULTS

Anaesthetised rabbits
Baseline measurements prior to the commencement of each drug protocol are shown in Table 1 . Ejection fraction was decreased and Tau increased differences between drug baseline variables.
Measurements of change from baseline over the measurement periods for PRSW, EDPVR, heart rate, mean arterial pressure, cardiac index, vascular resistance, ejection fraction and Tau are shown in Figure 1 . Both adrenaline (P=0.006) and dobutamine (P (PRSW), whereas milrinone did not (P=0.895).
creased by adrenaline only (P<0.001, vs. P=0.846 dobutamine; 0.100 milrinone). Both adrenaline (P<0.001) and dobutamine (P=0.006) decreased Tau, whereas milrinone did not (P=0.339). Adrenaline caused a dose-dependent fall in heart rate (P<0.001), whereas both dobutamine and milrinone caused dose-dependent tachycardia (P=0.006 and 0.011). Although there were trends of increased vascular resistance with adrenaline (P=0.065) and decreased vascular resistance with dobutamine (0.059), only (P<0.001). This was associated with increased mean arterial pressure with adrenaline (P<0.001) and dobutamine (P=0.009), but a decrease with milrinone Baseline variables are presented as: mean±standard error of the mean. MAP: mean arterial pressure, RAP: right atrial pressure, SVRI: systemic vascular resistance index, PRSW: preload recruitable stroke work, EDPVR: end diastolic pressure volume relationship, P: the RM-ANOVA statistic comparing differences between baseline variables. (P<0.001). Milrinone caused an increase in ejection fraction (P<0.001), as did dobutamine (P=0.020), whereas adrenaline did not alter EF (P=0.215). All three drugs increased cardiac index (P=0.036 adrenaline; P = 0.020 dobutamine; P<0.001 milrinone). There P=0.628 adrenaline; P=0.358 dobutamine; P=0.288 milrinone).
The relationship between contractility versus vascular resistance relative to baseline values is shown in Figure 2 . For adrenaline, as contractility increased, there was associated vasoconstriction. Milrinone caused the greatest degree of vasodilation, without increase in contractility. Dobutamine caused a reduction in vascular resistance with increased dose, but additionally a reduction in contractility from the third to fourth dose.
Isolated atrial tissue
The agonist concentration-response curves for all three drugs for atrial rate and left atrial force are ences between drugs for the baseline measurements (P in atrial rate (adrenaline P<0.001; dobutamine P=0.02; milrinone P=0.001). Milrinone caused a pared to adrenaline and dobutamine (P=0.003). All (adrenaline P=0.003; dobutamine P=0.002; milrinone P=0.008), but the magnitude of response was much less with milrinone than with adrenaline or dobutamine.
The pEC 50 (-log M±SEM) values for absolute rate were: adrenaline 7.12±0.15; dobutamine 6.51± 0.19 and milrinone 6.22±0.40. The pEC 50 values for absolute force were: adrenaline 6.21±0.52; dobutamine 5.85±1.07 and milrinone 6.34±0.45. However, milrinone did not achieve a satisfactory plateau in the force response.
DISCUSSION
Our study shows that the predominant action of milrinone in vivo is vasodilation. Although we have demonstrated an inotropic effect in atrial tissue, the magnitude was small at high concentration. By contrast, dobutamine causes increased contractility with minimal change in vascular resistance, with balance of these actions resulting in maintenance of mean arterial pressure and improvement in cardiac index. Adrenaline caused a dose-dependent increase in contractility, but at higher doses a trend towards vasoconstriction was seen, thereby attenuating the expected increase in ejection fraction and cardiac index and slowing the heart rate, presumably via showed improved early myocardial relaxation, though an increase in end-diastolic stiffness was seen with adrenaline indicating impaired diastolic function during the late passive stage of relaxation. There were no effects on diastolic function with milrinone.
Ejection phase measurements of contractility such as cardiac output or ejection fraction, or the maximal dP/dt, are sensitive to changes in preload or afterload 15 (decreased vascular resistance causes earlier opening of the aortic valve, thereby limiting the rise in dP/dt). Pressure-volume loops acquired during a rapid reduction in preload allow measurements of myocardial contractility and diastolic function that are relatively insensitive to ventricular loading conditions 10 .This is of particular importance when evaluating drugs that affect both ventricular function as well as altering vascular resistance. Improvements in ejection phase indices of left ventricular function, such as cardiac output or ejection fraction, can be caused by either increases in contractility or falls in vascular resistance, or by a combination of both mechanisms. By using pressure-volume loops, we were able to separate the components of contractility, diastolic function are in contrast to those of Kishi et al 16 who found an inotropic effect with milrinone infusion in rats using pressure-volume loops. Their method differed from this study by the use of aortic occlusion rather than vena caval occlusion to rapidly alter loading conditions. This has been shown to cause additional myocardial inotropism (when compared to caval distal perfusion 17 . The increase in contractility was small and in a similar magnitude to that shown in our atrial tissue preparation.
Milrinone did not have any effect on diastolic Monrad et al 6 who found improved indices of diastolic function in patients with advanced congestive heart failure treated with milrinone, including improved effects of right ventricular dysfunction (leading to right ventricular hypertension and dilation) on left ventricular diastolic function. It is possible that systemic and pulmonary vasodilation 5 following milrinone administration could decompress the right ventricle and reduce the physical effect of the right ventricle compressing the left ventricle. isolated atrial tissue, as the latter assessed responses seen in vivo. The concentration of drug used in the anaesthetised rabbit preparation was within the 10 -6 to 10 -5 M range, assuming a plasma volume of 60 ml/kg in the animals, and therefore effects in the atrial tissue preparation should be representative of the in vivo data. Although there was a rise in left atrial force with milrinone, it did not reach a plateau in adrenaline or dobutamine.
Clinical indications for milrinone are decompensated congestive heart failure and acute ventricular dysfunction following cardiopulmonary bypass. In cardiac surgery, it has also been advocated as a of graft spasm 18 . During cardiac surgery, with the heart under direct vision, it is easy for the surgeon to observe (mostly right ventricle) the improvement in systolic performance with milrinone 5 . Persistent and often severe hypotension is frequent and commonly requires catecholamine vasopressor infusion to maintain adequate blood pressure. This improvement in systolic performance with hypotension can be explained by the predominant effect of milrinone of vasodilation.
The relationship between vasodilation and inotropy is illustrated in Figure 2 , where the change in SVRI from baseline is plotted against the change in PRSW from baseline. Adrenaline is shown to increase both contractility and vascular resistance, such that at higher doses the use of adrenaline is likely to produce considerable ventricular-arterial mismatch. Conversely, milrinone caused a marked decrease in SVRI consistent with a predominant vasodilator action. Of the three drugs tested, dobutamine appears elicited increases in contractility with modest vascular low doses and progressively fell thereafter), which will enhance ejection as the dose is increased and improve ventricular-arterial matching. Of note, though, is a reduction in contractility with dobutamine from the third to fourth dose, which could indicate a partial agonist effect of dobutamine at higher doses. This would have the clinical implication that progressively higher doses of dobutamine may be ineffective. It may be more effective to add a second inotrope to dobutamine once the effect of a moderate dose is achieved.
Milrinone acts by inhibiting the breakdown of cAMP generated from endogenous catecholamine activity. In clinical situations where circulating endogenous catecholamine levels are high due to a 'stress response' (such as acute heart failure, or following cardiopulmonary bypass) then cAMP production will be high and the effect of milrinone will increase it further, leading to enhanced contractility. When the catecholamine levels fall, or in states of catecholamine depletion, or with catecholamine receptor down-regulation, then intracellular cAMP production will be decreased and the effect of milrinone on contractility may be minimal and vasodilation will be the predominant effect. Milrinone will be more effective when cAMP production is high and less effective when it is low. This is of particular clinical concern if the dose of milrinone is increased to treat progressive heart failure as contractility may not be enhanced but rather dose-dependent vasodilation will occur; or in renal failure where milrinone elimination is reduced, leading to higher plasma concentrations of the drug 19 .
Milrinone held great potential as an inodilator for the treatment of chronic congestive heart failure. Several studies raised concern about increased morbidity and mortality, culminating in the PROMISE study, which showed a 28% increase in mortality, with adverse effects greatest in those with the most severe symptoms 8, 20 . In a more recent study 9 , patients with acute exacerbations of chronic heart failure were randomised to receive 48 hours of intravenous receiving milrinone, but there was a higher incidence of sustained hypotension and atrial arrhythmias. The and mortality has raised doubt whether milrinone has a role in the management of haemodynamic crises requiring inotropic therapy 21 . In conditions of and may further contribute to persistent vasodilation.
Limitations
Several limitations must be considered. Our rabbits were young and had normal hearts, which may behave differently from elderly patients with failing hearts encountered in clinical practice. Similarly, we cannot evaluate the effects of disease co-morbidity such as hypertension, diabetes, or renal failure in our animal preparations. We have used an open chest preparation, requiring positive pressure ventilation, with the pericardium incised, which may affect right ventricular constraint and diastolic function. Although these conditions are similar to those encountered during cardiac surgery, they are different from a nonanaesthetised patient with heart failure. It would have been ideal to randomise the order in which the drugs were administered, but this was not possible because of the long half-life of milrinone. Baseline ejection fraction was decreased (though still normal) and Tau was increased in the milrinone group, indicating possible fatigue of the animal preparation over time. All other baseline variables were not different between groups and the magnitude of change for ejection fraction and Tau were relatively small. The doses of drugs used in this study are greater than would rabbits and humans. The dose range was determined from pilot experiments aiming for at least a 50% rise in contractility with adrenaline at mid-dose levels with dobutamine and milrinone matched on a comparative μg/kg basis, thereby allowing a range that would simulate low dose to high dose in clinical practice.
CONCLUSION
The predominant effect of milrinone in vivo is vasodilation and the inotropic effect was weak. Adrenaline is an inoconstrictor at high dose and dobutamine may have partial agonist effects at high
